Primecap Management Co. CA Lowers Stock Position in LivaNova PLC (NASDAQ:LIVN)

Primecap Management Co. CA reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 15.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,754,060 shares of the company’s stock after selling 873,746 shares during the quarter. Primecap Management Co. CA owned about 8.76% of LivaNova worth $220,161,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Nordea Investment Management AB raised its stake in shares of LivaNova by 22.2% during the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock worth $3,188,000 after acquiring an additional 12,470 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new position in shares of LivaNova during the fourth quarter worth approximately $1,954,000. KBC Group NV raised its stake in shares of LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after acquiring an additional 56,580 shares in the last quarter. Rhumbline Advisers raised its stake in shares of LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock worth $8,240,000 after acquiring an additional 899 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of LivaNova by 17.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after acquiring an additional 93,311 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LIVN has been the topic of several research reports. Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group cut their target price on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and issued a $64.00 target price on shares of LivaNova in a report on Monday. Finally, StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.17.

LivaNova Stock Performance

NASDAQ:LIVN opened at $41.41 on Tuesday. The stock has a market cap of $2.25 billion, a P/E ratio of 98.60 and a beta of 1.10. The firm’s fifty day simple moving average is $45.88 and its 200 day simple moving average is $49.01. LivaNova PLC has a twelve month low of $36.85 and a twelve month high of $64.48. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.